Kooij Louise Frederika sold $1.2M of NAMS
Kooij Louise Frederika (Chief Accounting Officer) sold 40,000 shares of NewAmsterdam Pharma Co N.V. (NAMS) at an average of $30.20 ($30.20–$30.73, $1.21M total) across 2 trades on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CFO’s open-market sale under a 10b5-1 plan is disclosed, but the text contains no new company performance, clinical, regulatory, or deal information.
Market read
Traders may note the insider sale for sentiment, but it is unlikely to change valuation absent other catalysts.
What to watch
The filing does not state tax, diversification, or other personal drivers; without follow-on buys or changes in trading patterns, signal quality remains low.
Background
The article is an SEC Form 4 insider transaction disclosure for NewAmsterdam Pharma (NAMS).
Ticker impact
NewAmsterdam Pharma insider Form 4 shows CFO Kooij Louise Frederika sold about 40,000 shares for roughly $1.21M under a 10b5-1 plan.
Likely limited immediate price impact; any effect is more sentiment-driven than fundamental.
The filing is a disclosed open-market sale with a pre-arranged 10b5-1 plan, and the article provides no accompanying operational or guidance change.
Market effects
Minimal; this is company-specific insider trading with no sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Because it is a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish expectations, so traders may ignore it.
Key entities
- issuerNewAmsterdam Pharma Co N.V.
Subject of the Form 4 insider sale disclosure.
- insiderKooij Louise Frederika
Chief Accounting Officer who sold shares.
